CRISPR THERAPEUTICS AG (CRSP)
CH0334081137 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 389.48M | 211.90M | 923.00M | 1.17B | 943.80M | |||
| Marketable Securities | 1.30B | 1.60B | 1.46B | 521.70M | N/A | |||
| Receivables | 200.00M | 0.00 | 300.00K | 100.00K | 100.00K | |||
| Other Current Assets | 14.39M | 37.70M | 38.10M | 26.10M | 43.70M | |||
| Total Current Assets | 1.91B | 1.85B | 2.42B | 1.72B | 987.50M | |||
| Non-Current Assets | ||||||||
| PPE Net | 305.94M | 320.60M | 312.00M | 93.00M | 72.80M | |||
| Investments And Advances | 1.97M | 53.10M | N/A | N/A | N/A | |||
| Intangibles | 16.00K | 100.00K | 100.00K | 200.00K | 200.00K | |||
| Other Non-Current Assets | 13.57M | 16.30M | 22.20M | 18.10M | 6.10M | |||
| Total Non-Current Assets | 321.49M | 390.10M | 334.40M | 111.40M | 79.30M | |||
| TOTAL ASSETS | 2.23B | 2.24B | 2.75B | 1.83B | 1.07B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 60.96M | 93.50M | 103.20M | 65.10M | 38.70M | |||
| Accounts Payable | 38.15M | 27.40M | 14.80M | 9.10M | 5.90M | |||
| Other Current Liabilities | 9.68M | 200.00K | 1.90M | 20.00M | 12.50M | |||
| Total Current Liabilities | 108.79M | 121.10M | 119.90M | 94.30M | 57.10M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 237.98M | 246.50M | 232.50M | 69.50M | 70.20M | |||
| Total Non-Current Liabilities | 237.98M | 246.50M | 232.50M | 69.40M | 70.20M | |||
| TOTAL LIABILITIES | 346.77M | 367.60M | 352.40M | 163.70M | 127.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -999.70M | -846.10M | -195.90M | -573.60M | -224.70M | |||
| Additional Paid In Capital | 2.88B | 2.73B | 2.60B | 2.24B | 1.16B | |||
| Minority Interest | N/A | N/A | N/A | N/A | N/A | |||
| Common Shares | 2.50M | 2.40M | 2.40M | 2.30M | 1.80M | |||
| Treasury Stock | -62.00K | -100.00K | -100.00K | -100.00K | -100.00K | |||
| Other Shareholders' Equity | 1.91M | -15.60M | -5.10M | -100.00K | 0.00 | |||
| Shares Outstanding | 80.04M | 78.50M | 77.00M | 73.90M | 60.80M | |||
| Tangible Book Value per Share | 23.52 | 23.89 | 31.16 | 22.52 | 15.45 | |||
| Total Shareholders' Equity | 1.88B | 1.88B | 2.40B | 1.66B | 939.40M | |||
| TOTAL LIABILITIES AND EQUITY | 2.23B | 2.24B | 2.75B | 1.83B | 1.07B | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 17.54 | 15.30 | 20.16 | 18.20 | 17.29 | |||
| Return On Assets (ROA) | -6.89% | -28.99% | 13.73% | -19.09% | 6.27% | |||
| Return On Equity (ROE) | -8.16% | -34.67% | 15.74% | -20.97% | 7.12% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | 11.21% | N/A | 3.65% | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | 25.09% | N/A | 3.65% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | N/A | 25.09% | N/A | 3.65% | |||
All data in USD